Brand Name
Omvoh
Generic Name
Mirikizumab-Mrkz
View Brand Information FDA approval date: October 26, 2023
Classification: Interleukin-23 Antagonist
Form: Injection, Kit
What is Omvoh (Mirikizumab-Mrkz)?
OMVOH is indicated for the treatment of: moderately to severely active ulcerative colitis in adults. moderately to severely active Crohn's disease in adults. OMVOH TM is an interleukin-23 antagonist indicated for the treatment of: moderately to severely active ulcerative colitis in adults moderately to severely active Crohn's disease in adults
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
MIrikizumab in UC - a Real-woRld prOspective multicenteR Registry
Summary: The goal of this observational study is to learn about how effective mirikizumab (Omvoh) is when treating patients with ulcerative colitis (UC) Does mirikizumab (Omvoh) lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed mirikizumab (Omvoh) as part of their regular medical care for UC will answer online survey questions about their bowel habits for 1 yea...